GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...

Ozempic may lower dementia and nicotine dependence risk in people with type 2 diabetes. A recent study shows fewer cognitive deficits and lower smoking rates compared with other diabetes drugs.

Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.